PMID- 38493844
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240415
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 655
DP  - 2024 Apr 25
TI  - Red blood cell membrane-camouflaged gold-core silica shell nanorods for cancer 
      drug delivery and photothermal therapy.
PG  - 124007
LID - S0378-5173(24)00241-2 [pii]
LID - 10.1016/j.ijpharm.2024.124007 [doi]
AB  - Gold core mesoporous silica shell (AuMSS) nanorods are multifunctional 
      nanomedicines that can act simultaneously as photothermal, drug delivery, and 
      bioimaging agents. Nevertheless, it is reported that once administrated, 
      nanoparticles can be coated with blood proteins, forming a protein corona, that 
      directly impacts on nanomedicines' circulation time, biodistribution, and 
      therapeutic performance. Therefore, it become crucial to develop novel 
      alternatives to improve nanoparticles' half-life in the bloodstream. In this 
      work, Polyethylenimine (PEI) and Red blood cells (RBC)-derived membranes were 
      combined for the first time to functionalize AuMSS nanorods and simultaneously 
      load acridine orange (AO). The obtained results revealed that the RBC-derived 
      membranes promoted the neutralization of the AuMSS' surface charge and 
      consequently improved the colloidal stability and biocompatibility of the 
      nanocarriers. Indeed, the in vitro data revealed that PEI/RBC-derived membranes' 
      functionalization also improved the nanoparticles' cellular internalization and 
      was capable of mitigating the hemolytic effects of AuMSS and AuMSS/PEI nanorods. 
      In turn, the combinatorial chemo-photothermal therapy mediated by 
      AuMSS/PEI/RBC_AO nanorods was able to completely eliminate HeLa cells, 
      contrasting with the less efficient standalone therapies. Such data reinforce the 
      potential of AuMSS nanomaterials to act simultaneously as photothermal and 
      chemotherapeutic agents.
CI  - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Rodrigues, Carolina F
AU  - Rodrigues CF
AD  - CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. 
      Infante D. Henrique, 6200-506 Covilha, Portugal.
FAU - Correia, Ilidio J
AU  - Correia IJ
AD  - CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. 
      Infante D. Henrique, 6200-506 Covilha, Portugal; CIEPQPF - Departamento de 
      Engenharia Quimica, Universidade de Coimbra, Rua Silvio Lima, 3030-790 Coimbra, 
      Portugal; AEROG-LAETA, Aerospace Sciences Department, Universidade da Beira 
      Interior, Covilha, Portugal. Electronic address: icorreia@ubi.pt.
FAU - Moreira, Andre F
AU  - Moreira AF
AD  - CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. 
      Infante D. Henrique, 6200-506 Covilha, Portugal; CPIRN-UDI/IPG - Centro de 
      Potencial e Inovacao em Recursos Naturais, Unidade de Investigacao para o 
      Desenvolvimento do Interior do Instituto Politecnico da Guarda, Avenida Dr. 
      Francisco de Sa Carneiro, No. 50, 6300-559 Guarda, Portugal. Electronic address: 
      afmoreira@fcsaude.ubi.pt.
LA  - eng
PT  - Journal Article
DEP - 20240315
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 7440-57-5 (Gold)
RN  - 0 (Antineoplastic Agents)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Humans
MH  - HeLa Cells
MH  - Photothermal Therapy
MH  - Erythrocyte Membrane
MH  - Silicon Dioxide
MH  - Gold
MH  - Tissue Distribution
MH  - Phototherapy
MH  - *Antineoplastic Agents
MH  - *Nanotubes
MH  - Doxorubicin/pharmacology
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - Cancer
OT  - Drug delivery
OT  - Gold core silica shell nanorods
OT  - PEI
OT  - Photothermal therapy
OT  - RBC-derived membranes
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/18 00:42
MHDA- 2024/04/15 06:43
CRDT- 2024/03/17 20:26
PHST- 2023/11/27 00:00 [received]
PHST- 2024/02/27 00:00 [revised]
PHST- 2024/03/14 00:00 [accepted]
PHST- 2024/04/15 06:43 [medline]
PHST- 2024/03/18 00:42 [pubmed]
PHST- 2024/03/17 20:26 [entrez]
AID - S0378-5173(24)00241-2 [pii]
AID - 10.1016/j.ijpharm.2024.124007 [doi]
PST - ppublish
SO  - Int J Pharm. 2024 Apr 25;655:124007. doi: 10.1016/j.ijpharm.2024.124007. Epub 
      2024 Mar 15.